Purpose: This study aims to investigate the effect of GnRHa on GH-IGF-1 axis and to evaluate if −202 A/C IGFBP-3 promoter polymorphism affects the growth velocity during treatment on girls with central precocious puberty (CPP).
Methods: Data was collected from 97 girls, diagnosed under 9 year of age and treated by GnRHa for at least 1 year in Kangdong Sacred Heart Hospital between 20142015. Their body height, weight, Δ Height standard deviation score (SDS), serum IGF-1 and IGFBP-3 concentrations and bone age were measured at the start and after a year of GnRHa treatment. −202 A/C IGFBP-3 promoter polymorphism were analyzed. Possible correlations between the variables were calculated.
Results: During the treatment, height SDS, IGF-1 SDS, IGFBP-3 SDS and IGF-1/IGFBP-3 ratio significantly decreased. There were significant correlations between serum IGF-1 concentration and Δ Height SDS (r=0.405, p=0.000), and between serum IGFBP-3 concentration and Δ Height SDS (r=0.228, P=0.025). C allele had significant correlation with serum IGFBP-3 concentration (P=0.004) but had no significant correlation with Δ Height SDS (P=0.947). IGF-1 decreased in C allele group after the treatment (P=0.049), and IGFBP-3 decreased regardless of allele group after the treatment (AA P=0.012, AC&CC P=0.001).
Conclusion: The results suggest that the growth velocity during GnRHa treatment may be related to serum IGF-1 and IGFBP-3 concentrations thus GnRHa may affect GH-IGF-1 axis.
27 - 29 Sep 2018
European Society for Paediatric Endocrinology